John Rim has become Samsung Biologics’ new president and CEO.
Rim has been the South Korean CDMO’s executive vice president for the last three years. The company says he has been instrumental in rapidly expanding the manufacturing portfolio across Samsung Biologics and for continuous operational excellence in Plant 3, the world’s largest manufacturing capacity at a single site, which opened in 2018.
Rim has more than 30 years’ experience in the biopharmaceutical industry. Prior to joining Samsung Biologics in 2018, he worked for Genentech/Roche in senior global leadership roles in technical operations, product development, and R&D in the US and Europe. Rim has also held senior leadership roles with Astellas Pharmaceuticals in general management, sales & marketing, technical operations, customer service, business development, and strategic planning. He began his career as a management consultant with Booz, Allen & Hamilton consulting to pharmaceutical companies in the US and Europe.
“I am deeply grateful and excited by the opportunity to lead Samsung Biologics into the next decade,” said Rim. “This is an extraordinary company, unparalleled in its phenomenal growth and dedication to client satisfaction, made possible by the company’s unrelenting vision and passion, and business execution by great people whom I will have the privilege to lead as CEO.”
Samsung Biologics has seen a continuous increase in sales volume across all plants this year, and has been expanding its global business, including the opening of its first US CDO R&D Center in San Francisco. The company also recently commenced construction of its fourth plant, which is due to start operations in 2022.